Zusammenfassung
Maligne Tumoren sind durch Gewebeinvasion und Metastasierung charakterisiert, welche mit der Bildung und dem Abbau von Strukturelementen in der Nachbarschaft der Tumorzellen einhergehen. Die zu durchdringenden Gewebestrukturen bestehen dabei vorwiegend aus Proteinen, Proteoglykanen und Kollagen, so daß es sich bei den zur Invasion und Metastasierung notwendigen Substanzen vorwiegend um Proteasen handelt. Bei den korrelierenden Umbauprozessen sind prokoagulatorische Substanzen und Faktoren der Fibrinolyse über die Bildung und den Abbau einer „Fibrin-Fibronectin-Matrix“ direkt, und über die Aktivierung anderer Proteasesy-steme indirekt beteiligt [7, 8, 16].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Astedt B, Holmberg L (1976) Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261:595–597
Blasi F (1988) Surface receptors for urokinase plasminogen activator. Fibrinolysis 2:73–84
Carniolo SM, Markus G, Piver MS (1987) Plasminogen activator content of gynecological tumors and their metastases. Gynecol Oncol 26:364–373
Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar H, Rochefort H (1989) Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res 49:3904–3909
Clark GM, Lynn G, Dressier MA, Owens MA, Pounds G, Oldaker T, McGuire WL (1989) Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627–632
Cubellis MV, Wun T, Blasi F (1990) Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAL-1. EMBO J 9:1079–1085
Dano KP, Andreasen A, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139
Dvorak HF (1986) Tumors: Wounds that do not heal. N Engl J Med 315:1650–1659
Graeff H (1991a) Klinische und prognostische Bedeutung der tumorassoziierten Fibrinolyse in der Onkologie. Fibrinolyse 3:1–3
Graeff H, Jänicke F, Schmitt M (1991 ) Klinische und prognostische Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie. Geburtsh Frauenheilkd 51:90–99
Graeff H, Harbeck N, Pache L, Wilhelm O, Jänicke F, Schmitt M (1992) Prognostic Impact and Clinical Relevance of Tumor-associated Proteases in Breast Cancer. Fibrinolysis 4:45–53
Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69–78
Jänicke F, Schmitt M, Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Thromb Hemost 17:303–312
Jänicke F, Schmitt M, Graeff H (1992) Plasminogen activators and the inhibitor PAI-1 are correlated to invasive and metastatic capacity of breast cancer. Fibrinolysis Suppl 6, 108:283 (abstr.)
Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Günzler WA, Jänicke F, Graeff H (1991) Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzym urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266:5147–5152
Markus G (1988) The relevance of plasminogen activators to neoplastic growth. Review of recent literature. Enzyme 40:158–172
Miles A, Plow EF (1988) Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 2:61–71
Rochefort H, Caponi F, Garcia M, Cavailles V, Freiss G, Chambon M, Morisset M, Vignon F (1987) Estrogen-induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? J Cell Biochem 35:17–29
Rochefort HJ, Augereau P, Briozzo P, Brouillet P, Caponi F et al. (1989) Estrogen induced cathepsin D in breast cancer: From biology to clinical applications. In: Rich MA, Hager JC, Keydar I (eds) Breast cancer, progress in biology, clinical management and prevention. Kluwer Academic Publishers, Boston, pp 171–186
Schneider W, Südhoff T (1991) Fibrinolyse und Tumorkrankheit. Fibrinolyse 3:4–9
Sloane BF, Dunn JR, Honn KV (1981) Lysosomal cathepsin B: correlation with metastatic potential. Science 212:1151–1153
Spyratos F, Maudelonde T, Brouillet et al. (1989) Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet 8672:1115–1118
Tandon AT, Clark GM, Chamness GC, Chrigwin JM, McGuire WL (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297–302
Trygvasson K (1989) Extracellular matrix and its enzymatic degradation in tumor invasion. (A review) In: Liotta AL (ed) Influence of tumor development on the host. Kluwer Academic Publishers, Dordrecht, pp 72–83
Wilhelm O, Hafter R, Coppenrath E, Pflanz MA, Schmitt M, Babic R, Linke R, Gössner W, Graeff H (1988) Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res 48:3507–3514
Wilhelm O, Hafter R, Hensche A, Schmitt M, Graeff H (1990) Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 75:1673–1678
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ehrenforth, S. et al. (1993). Tumorassoziierte Fibrinolyse unter besonderer Berücksichtigung der klinischen und prognostischen Bedeutung von u-PA, t-PA und PAI-1 bei gynäkologischen Tumorerkrankungen. In: Scharrer, I., Schramm, W. (eds) 23. Hämophilie-Symposion. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78359-3_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-78359-3_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56955-8
Online ISBN: 978-3-642-78359-3
eBook Packages: Springer Book Archive